Atezolizumab

(Tecentriq®)

Tecentriq®

Drug updated on 12/11/2024

Dosage FormInjection (intravenous; 840 mg/14 mL [60 mg/mL], 1200 mg/20 mL [60 mg/mL])
Drug Classhuman programmed death receptor-1 (PD-1)-blocking antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on 1% of tumor cells, as determined by an FDA-approved test
  • Indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained 50% of tumor cells [TC 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering 10% of the tumor area [IC 10%]), as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations
  • Indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations
  • Indicated in combination with paclitaxel protein-bound and carboplatin for the first line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations
  • Indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving Tecentriq
  • Indicated in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
  • Indicated in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy
  • Indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma
  • Indicated for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 87 systematic review(s)/meta-analysis(es). [1-87]
  • Hepatocellular Carcinoma (HCC): Atezolizumab combined with bevacizumab demonstrated superior overall survival (OS) and progression-free survival (PFS) compared to sorafenib in advanced HCC, consistently ranking as one of the most effective first-line treatments. This combination also outperformed lenvatinib in terms of OS and has been highlighted in systematic reviews and network meta-analyses as offering the best overall effectiveness in HCC.
  • Non-Small Cell Lung Cancer (NSCLC): In advanced non-squamous NSCLC, atezolizumab combined with chemotherapy improved both OS and PFS compared to chemotherapy alone, though atezolizumab monotherapy showed lower efficacy, particularly in programed death ligand 1 (PD-L1) high expressors. For this subgroup, pembrolizumab combined with chemotherapy generally ranked higher in efficacy compared to atezolizumab plus chemotherapy.
  • Small Cell Lung Cancer (SCLC): In extensive-stage SCLC, the combination of atezolizumab with chemotherapy demonstrated improved OS and PFS over chemotherapy alone. This combination was generally favored over other immune checkpoint inhibitors (ICIs) like durvalumab for efficacy outcomes in extensive-stage SCLC.
  • Comparative Effectiveness in Key Cancer Types: For HCC, atezolizumab plus bevacizumab showed superior outcomes in OS and PFS compared to both sorafenib and lenvatinib. In NSCLC, pembrolizumab plus chemotherapy was generally more effective for PD-L1 high expressors, while in SCLC, atezolizumab plus chemotherapy was more effective in enhancing OS and PFS compared to durvalumab with chemotherapy.
  • HCC: In patients treated with atezolizumab plus bevacizumab, adverse events were reported more frequently, particularly grade 3 or higher events in Child-Pugh B patients compared to Child-Pugh A patients. Common adverse events included hypertension and proteinuria, suggesting that the Child-Pugh B group may require close monitoring for adverse effects.
  • NSCLC: Atezolizumab combined with chemotherapy led to increased treatment-related adverse events, especially grade 3-5 events, compared to chemotherapy alone. The most common adverse events were respiratory issues, endocrinological effects, and skin reactions.
  • Small Cell Lung Cancer (SCLC): When combined with chemotherapy, atezolizumab was associated with a higher incidence of adverse events than chemotherapy alone, including neutropenia, anemia, and fatigue. Hematological toxicities were notably frequent, indicating a need for regular monitoring.
  • Comparative Safety Across Indications: For HCC, atezolizumab plus bevacizumab showed a higher incidence of adverse events than sorafenib. In NSCLC, atezolizumab combined with chemotherapy had comparable but elevated rates of specific adverse events (e.g., hypertension) relative to pembrolizumab plus chemotherapy. In SCLC, the safety profile of atezolizumab with chemotherapy was similar to that of durvalumab with chemotherapy.
  • HCC: Patients with viral hepatitis demonstrated better responses to immune checkpoint inhibitor (ICI)-based therapies, particularly with the combination of atezolizumab and bevacizumab. However, Child-Pugh B patients experienced higher rates of adverse events and had shorter progression-free survival (PFS) and OS compared to Child-Pugh A patients, indicating a need for cautious monitoring in the Child-Pugh B group.
  • NSCLC: Efficacy of atezolizumab was consistent across age groups, with no significant differences in outcomes between patients aged 75 years and older and younger patients, though older patients experienced more adverse events. Additionally, patients with high PD-L1 expression levels responded more favorably to atezolizumab combined with chemotherapy, indicating that PD-L1 expression status may guide treatment decisions.

Product Monograph / Prescribing Information

Document TitleYearSource
Tecentriq (atezolizumab) Prescribing Information.2024Genentech, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies2024International Journal of Molecular Sciences
Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis2024Lung Cancer
Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis2024BMC Cancer
First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis2024 Therapeutic Advances in Medical Oncology
Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports2024Cancers
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis2024Liver Cancer
Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system2024Frontiers in Immunology
First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression >/=50%: a network meta-analysis of randomized controlled trials2024Frontiers in Oncology
The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis2024Therapeutic Advances in Gastroenterology
Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis2024Thoracic Cancer
A Network Meta-analysis of the Efficacy of Drug Therapy in First-line Treatment of Advanced Hepatocellular Carcinoma2024Journal of Gastrointestinal and Liver Diseases
Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials2024Cancer Communications
Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis2023Liver Cancer
Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis2023Therapeutic Advances in Chronic Disease
Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis2023Clinical and Experimental Hepatology
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis2023EClinicalMedicine
Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review2023Annals of Translational Medicine
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis2023Chinese Medical Journal
Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials2023Annals of Medicine
Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis2023Frontiers in Immunology
Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis2023BMC Cancer
Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis2023Medicine
Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials2023Frontiers in Oncology
First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis2023Journal of Cancer Research and Therapeutics
Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials2023Frontiers in Oncology
Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis2023Heliyon
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis2023PLoS One
First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis2023Frontiers in Public Health
Anti-TIGIT therapies for solid tumors: a systematic review2023ESMO Open
Baseline risk factors associated with immune related adverse events and atezolizumab2023Frontiers in Oncology
First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis2023Liver Cancer
Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis2023Lung Cance
Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis2023Human Vaccines & Immunotherapeutics
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis2023 Lung Cancer
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis2023Current Oncology
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity2023Journal of Comparative Effectiveness Research
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer2023Journal of Comparative Effectiveness Research
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer2022Frontiers in Immunology
First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review2022Current Oncology
Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis2022Discover Oncology
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials2022European Journal of Cancer
Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis2022Frontiers in Immunology
Electrolyte Abnormalities Associated With the Use of Atezolizumab - A Systematic Review2022Journal of Community Hospital Internal Medicine Perspectives
Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies2022Frontiers in Oncology
Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life2022Current Medical Research and Opinion
What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis2022Frontiers in Immunology
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis2022ESMO Open
Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials2022Journal of Thoracic Oncology
Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials2022Cancer Immunology, Immunotherapy
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis2022Oncology and Therapy
Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis2022Thoracic Cancer
Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies2022Clinical Cancer Research
Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials2022Cancer Research and Treatment
First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 >/= 50%: a systematic review and network meta-analysis2022Cancer Immunology, Immunotherapy
Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario2021Canadian Liver Journal
First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials2021Frontiers in Oncology
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review2021World Journal of Gastrointestinal Oncology
The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis2021BMC Cancer
Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis2021Frontiers in Oncology
Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis2021Thoracic Cancer
Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis2021Frontiers in Immunology
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)2021Gastroenterology
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis2021Therapeutic Advances in Medical Oncology
Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials2021World Journal of Gastroenterology
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer2021Critical Reviews in Oncology/Hematology
Efficacy of atezolizumab to treat non-small-cell lung cancer: a meta-analysis based on randomized clinical trials2021Die Pharmazie
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer2021The Cochrane Database of Systematic Reviews
Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis2021Medicine
Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials2021Journal of Hepatocellular Carcinoma
Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison2021Annals of Palliative Medicine
The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients2021Oncologist
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review2021Journal of the National Cancer Institute
Systematic review of first-line chemotherapy for chemo-naive extensive-stage small-cell lung cancer: network meta-analysis2020Therapeutic Advances in Medical Oncology
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer2020The Cochrane Database of Systematic Reviews
The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis2020Annals of Palliative Medicine
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma2020Cancers
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis2020JAMA Oncology
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis2020JAMA Network Open
Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis2020Journal of Oncology
Checkpoint inhibitors in advanced nonsmall-cell lung cancer; a Bayesian network meta-analysis2020Journal of Cancer Research and Therapeutics
Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities2020Critical Reviews in Oncology/Hematology
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis2020Oncoimmunology
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept2020Frontiers in Medicine
Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis2020Frontiers in Pharmacology
Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis2020International Immunopharmacology
Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)2019Artificial Cells, Nanomedicine, and Biotechnolog
Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies2019Clinical Lung Cancer,

Clinical Practice Guidelines